Governance Board

Overview

Governance Board

Research Board

View Robert Hartmayer Bio.
Bob Hartmayer has over 30 years of experience within the Pharmaceutical and Chemical Industry and has recently been named President and CEO, DSM Pharmaceutical Products. During his 17 years experience within DSM, Bob has held several Executive Leadership positions including: President of DSM Engineering Plastics Americas, President and Business Group Director of DSM Food Specialties; COO DSM Nutritional Products and President and Business Group Director DSM Elastomers. Prior to joining DSM, Bob has held various positions in the chemicals and plastics industry. Bob holds both a Bachelors of Science and a Masters in Chemical Engineering from Manhattan College in New York.

View Pieter de-Geus Bio.
Dr. de Geus (48) obtained his PhD in Biochemistry in 1986 from the University of Utrecht, the Netherlands, with a thesis on the protein-engineering of (phospho)lipid-degrading enzymes. He then held several research management positions in the areas of recombinant protein production, and engineering, at Plant Genetic Systems (Belgium), Unilever Research, Gist-Brocades and DSM (the Netherlands). In this period he worked on industrial development and (fermentative) production of enzymes, antibodies and secondary metabolites for applications in the agro-, consumer goods and pharmaceutical businesses. In 1997 he moved into the bio-pharmaceutical field when appointed site director of the contract manufacturing organization of DSM Biologics in Groningen (The Netherlands). There he managed the transition of the company from a development services company into a cGMP contract manufacturing company, with its first commercial product being approved by FDA mid-2004. In 2006, Dr. de Geus became Vice President R&D for the DSM Pharmaceutical Products (DPP) business group, head-quartered in Parsippany, NJ (USA). DPP is a global, leading supplier of contract manufacturing and development services to the pharmaceutical industry. In line with the group’s activities, Dr. de Geus’ responsibilities comprise research and technology advancement in the areas of biopharmaceutical manufacturing, API manufacturing and drug product final dosage form development. In addition to its own, strong, R&D resources, DPP also actively looks to in-source technology through partnerships and licensing arrangements. In this context, Dr. de Geus was one of the main initiators of the establishment of a research joint venture between DSM Biologics and Crucell (a leading Dutch biotech company) in Cambridge, MA, in 2006. This JV, Percivia, focuses on the development of the human cell technology platform, PER.C6® , for the production of biopharmaceutical proteins. Since the beginning of 2009, Dr. de Geus has additional responsibility as Vice President Pharmaceutical Strategy, within the Corporate Strategy and Acquisitions (CS&A) department of DSM, in Heerlen, the Netherlands.

View Ronald Brus Bio.
Dr. Ronald Brus is Crucell’s President and Chief Executive Officer. He has been a member of Crucell’s Management Committee since the Company’s incorporation and was formerly Chief Operating Officer (March 2003 to January 2004) and Chief Business Officer (October 2000 to February 2003). Prior to that, he was Executive Vice President Business Development after joining the Company in 1997. From 1994 to 1996 he was product planning physician at Forest Laboratories in New York and from 1990 to 1994 he was Medical Director for Zambon B.V. He holds a medical degree from the University of Groningen, the Netherlands.

View Arthur Lahr Bio.
Mr. Arthur Lahr is Crucell’s Chief Strategy Officer and Executive Vice President Business Development. He joined Crucell in April 2001 as Executive Director Business Development and became a member of the Management Committee in January 2004, Executive Vice President in January 2006 and assumed responsibility for European marketing & sales and company strategy in 2006. From 1994 to 2001 he was a consultant with McKinsey & Co. in the Netherlands and New York. Prior to that, he worked at Unilever. He holds a Masters in Business Administration from INSEAD and a Masters in Science in Applied Physics from the University of Delft, the Netherlands.

View Jaap Goudsmit Bio.
Dr. Jaap Goudsmit is Crucell’s Chief Scientific Officer and is responsible for all R&D activities. He became a member of Crucell’s Management Board in January 2004. He joined Crucell in 2001 as Senior Vice President Vaccine Research and became a member of Crucell’s Management Committee in July 2002. Prior to that, he held various positions at the Academic Medical Center at the University of Amsterdam and was Chairman of the Research Institute for Infectious Diseases and the Institute for Science Education. Since 1989 he has been a professor at the University of Amsterdam and the Academic Medical Center. He holds a medical degree and a PhD from the University of Amsterdam, the Netherlands.